Showing results (31-40 of 122) with videos related to

Sort By:
Pageof 13
Molecular Cancer Therapeutics|June 19, 2007
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cellsTanyel Kiziltepe, Teru Hideshima, Laurence Catley, et al.
Leukemia & Lymphoma|August 3, 2018
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUSXiaozhong Qian, Meletios A Dimopoulos, Michael Amatangelo, et al.
Haematologica|October 27, 2012
Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replicationIrena Misiewicz-Krzeminska, María E Sarasquete, Dalia Quwaider, et al.
Plos One|March 25, 2014
Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell linesTeresa Paíno, María E Sarasquete, Bruno Paiva, et al.
Annals of Hematology|July 2, 2011
Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myelomaEdvan de Queiroz Crusoe, Patricia Maiso, Diego Fernandez-Lazaro, et al.
British Journal of Haematology|December 19, 2006
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growthHiroshi Yasui, Teru Hideshima, Hiroshi Ikeda, et al.
Oncotarget|October 1, 2014
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone diseaseAntonio Garcia-Gomez, Javier De Las Rivas, Enrique M Ocio, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 14, 2021
Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa StudyEnrique M Ocio, Carmen Montes-Gaisán, Gabriela Bustamante, et al.
Blood|February 7, 2009
International prognostic scoring system for Waldenstrom macroglobulinemiaPierre Morel, Alain Duhamel, Paolo Gobbi, et al.
Leukemia Research|September 22, 2019
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemiaDaniel J DeAngelo, Alison R Walker, Richard F Schlenk, et al.
Pageof 13